Drugs / Irinotecan Liposomal
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07085273 | Aug 2025 → Dec 2026 expected | gastric cancer | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotecan Liposomal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07085273 ↗ |
| Route | Intravenous | “Irinotecan liposomal: 60 mg/m2, IV infusion, d1” NCT07085273 ↗ |